(PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). ...
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology. Tulisokibart was designed ...
IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed ...
Marks the Completion of NanoACTIV Integration Across the Company’s Entire Additively Manufactured and Wrought Titanium Spinal ...
FDA clearance and CE Mark for latest Affera™ Prism-2 Mapping Software expand cardiac mapping capabilities. CE Mark for ...
(Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its ...
The awards recognize two significant milestones for Masimo: the company's $9.9 billion acquisition by Danaher and the ...
Acquisition extends Resonant's European footprint and adds specialized calibration expertise, IOR/EOR reach, and partner ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO ...
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with ...
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results